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In December 2019, a novel coronavirus (SARS-CoV-2) which causes COVID-19 disease emerged from Wuhan in China. It subsequently spread to over 200 countries, with the World Health Organisation (WHO) declaring a pandemic in March 2020.^[@CR4396],[@CR4400]^ As of 21 May 2020, there have been 4.8 million confirmed cases of COVID-19, including 321,000 deaths.^[@CR4404]^ With the numbers rapidly increasing, there is an urgent need to develop effective treatment for symptomatic COVID-19 patients.

There has been a growing interest in the use of hydroxychloroquine and chloroquine in the prevention and treatment of COVID-19. For many years, these drugs have been used for the treatment of malaria, as well as for auto-immune conditions such as systemic lupus erythematosus and rheumatoid arthritis.^[@CR4408]^ However, findings from *in vitro* studies have shown both hydroxychloroquine and chloroquine to have an effect on SARS-CoV-2 by impairing replication of the virus.^[@CR4396]^ Potential side effects of these drugs are well documented and they most commonly cause vomiting, diarrhoea and gastrointestinal upset. However, more severe side effects have been reported and include retinopathy and QTc interval prolongation, which can result in ventricular arrhythmias and sudden cardiac death.1 Clinical trials have been ongoing to determine their effectiveness in treating patients with COVID-19.^[@CR4400],[@CR4416]^

The authors of this review did not disclose their search methodology and as such we were not able to repeat or corroborate their database search for appropriate studies. Details of the databases used, search parameters applied or if medical subject headings (MeSH) were utilised are not provided. It was also unclear if studies were included or excluded based on date restrictions, non-English language use or being unpublished/grey literature. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines do not appear to have been followed. Further, the authors did not detail if registries for randomised controlled trials were searched.

Several barriers and difficulties faced the authors in completing their review. Primarily due to the lack of high-quality evidence available on the use of hydroxychloroquine and chloroquine in the prevention and treatment of COVID-19. The studies that the authors included had significant heterogeneity and numerous limitations. These barriers; combined with poorly defined, non-comparable outcome measures, resulted in difficulty extracting and synthesising relevant data and therefore no useful statistical analyses could be carried out.

The authors employed narrative synthesis to describe the methods and results of each study. The narrative highlighted important and significant limitations with the studies included in this review. All of the studies were underpowered due to their small sample size.^[@CR4400],[@CR4422],[@CR4426],[@CR4430],[@CR4434],[@CR4438]^ Only one of the six studies was appropriately peer-reviewed; however the authors noted that concerns had previously been raised about this study.^[@CR4400]^ Three of the studies were uncontrolled.^[@CR4430],[@CR4434],[@CR4438]^ Two of the studies were non-randomised, open-label and unblinded.^[@CR4400],[@CR4434]^ Significant concerns were also raised about the study designs potentially incorporating inherent bias.^[@CR4400],[@CR4434]^ One study did not publish the treatment regimen prescribed to patients and also provided no methodology for the statistical analysis carried out.^[@CR4438]^ The majority of the studies did not define disease stage and severity of the patients, making it difficult to draw comparisons between studies. Alarmingly, one study included no intention to treat analysis; despite several excluded patients in the treatment arm either requiring ICU admission or dying.^[@CR4400]^

Currently, there is ongoing research, aimed at determining the effectiveness of hydroxychloroquine and chloroquine in COVID-19 care. Several of the authors in this review have disclosed potential conflicts of interest, as they are principal investigators (PIs) on four ongoing randomised controlled trials investigating the use of hydroxychloroquine in the prevention and treatment of COVID-19 in Catalonia, Canada and the United States. The National Institute for Health Research (NIHR) are also funding a Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE).^[@CR4462]^ This UK-based randomised controlled trial will initially look at the use of hydroxychloroquine in modifying the disease course, with the goal of preventing disease progression and reducing hospital admissions. A randomised controlled trial in Brazil investigated the safety and efficacy of chloroquine in patients with established severe COVID-19, however recruitment in the high dose arm was stopped due to potential safety hazards and concerns over an increase in patient mortality.^[@CR4466]^

Alarmingly, despite the current lack of evidence for the efficacy and effectiveness of hydroxychloroquine and chloroquine in COVID-19 prevention and treatment, several official guidelines have incorporated and suggested their use.^[@CR4470]^ Perhaps this correlates with the unprecedented pressure caused by the global pandemic, combined with excessive media coverage and public figure endorsements; despite the scarcity of evidence.

This review emphasises the importance of more robust, adequately powered, future randomised controlled trials into the use of hydroxychloroquine and chloroquine for COVID-19; prior to their recommendation in national guidelines. Studies would ideally categorise disease severity and symptomatology prior to participants being randomised into treatment and control groups. Future studies should also focus on meaningful and comparable clinical outcome measures around patient hospital admission, ICU admission and patient mortality. This would allow data from different studies to be more readily compared, synthesised and extrapolated to larger populations. With the current dearth of evidence, patients subjected to hydroxychloroquine and chloroquine may not only be receiving no clinical benefit from the drug but could be coming to harm.^[@CR4474]^
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• Current evidence is insufficient to support the use of hydroxychloroquine or chloroquine in the prevention and treatment of COVID-19.

• More robust, adequately powered, randomised controlled trials are required to determine if the drugs have a clinical benefit and can therefore be recommended for use.
